A Multicenter Phase II Trial of Induction Nimotuzumab Plus Gemcitabine and Carboplatin Followed by Surgery in Patients With Unresectable Stage III Squamous Cell Lung Carcinoma
Latest Information Update: 12 Dec 2024
Price :
$35 *
At a glance
- Drugs Carboplatin (Primary) ; Gemcitabine (Primary) ; Nimotuzumab (Primary)
- Indications Lung cancer
- Focus Therapeutic Use
- 10 Dec 2024 Status changed from recruiting to withdrawn prior to enrolment (Reason the study was stopped: No patients enrolled).
- 04 Sep 2024 Planned End Date changed from 1 Oct 2020 to 1 Oct 2027.
- 04 Sep 2024 Planned primary completion date changed from 1 Oct 2018 to 1 Oct 2025.